Method for treatment and storage of blood and blood products using endogenous alloxazines and acetate

1 . A fluid comprising:

at least one collected blood component; and

a blood component additive solution comprising

an endogenous alloxazine, and

acetate.

2 . The fluid of claim 1 wherein the endogenous alloxazine is riboflavin.

3 . The fluid of claim 1 wherein the at least one collected blood component comprises platelets.

4 . The fluid of claim 1 wherein the blood component additive solution further comprises physiological saline.

5 . The fluid of claim 4 wherein the physiological saline is 0.9% sodium chloride.

6 . The fluid of claim 3 further comprising plasma.

7 . The fluid of claim 6 wherein the volume of plasma is between 20-80 mL per 10 11 collected platelets.

8 . The fluid of claim 6 wherein the volume of plasma is between 30-60 mL per 10 11 collected platelets.

9 . The fluid of claim 1 wherein the at least one collected blood component has been pathogen reduced.

10 . A storage or additive solution comprising:

an endogenous alloxazine; and

acetate.

11 . The storage or additive solution of claim 10 wherein the endogenous alloxazine is riboflavin.

12 . The storage or additive solution of claim 10 further comprising physiological saline.

13 . The storage or additive solution of claim 12 wherein the physiological saline is 0.9% sodium chloride.

14 . A storage or additive solution consisting essentially of:

an endogenous alloxazine; and

acetate.

15 . The storage or additive solution of claim 14 wherein the endogenous alloxazine is riboflavin.

16 . The storage or additive solution of claim 15 wherein the riboflavin is in a concentration of about 500 μM per 35±5 mLs of solution.

17 . The storage or additive solution of claim 14 wherein the acetate is in a concentration of around 140±50 mM per 35±5 mLs of solution.

18 . A storage or additive solution consisting of:

riboflavin;

acetate; and

saline.

19 . A fluid which has been pathogen reduced consisting essentially of:

collected blood or blood components; and

a pathogen reduction solution consisting essentially of

photoproducts of a photosensitizer-like additive;

acetate; and

saline.

20 . The fluid of claim 19 wherein the collected blood or blood components further consists essentially of platelets and plasma.

21 . The fluid of claim 20 wherein the plasma is between 20-80 mL per 10 11 collected platelets.

22 . The fluid of claim 20 wherein the plasma is between 30-60 mL per 10 11 collected platelets.

23 . The fluid of claim 19 wherein the photoproducts of a photosensitizer-like additive are photoproducts of an endogenous photo sensitizer.

24 . A pathogen reduction solution comprising:

an endogenous alloxazine; and

acetate.

25 . The pathogen reduction solution of claim 24 further comprising saline.

26 . The pathogen reduction solution of claim 24 wherein the endogenous alloxazine further comprises riboflavin

27 . A pathogen reduction solution consisting of:

riboflavin;

acetate; and

saline.

28 . A method of pathogen reducing blood or collected blood components which may contain pathogens comprising:

(a) mixing an effective non-toxic amount of a mixture consisting essentially of an endogenous photosensitizer and acetate with the blood or collected blood component to make a mixed fluid; and

(b) exposing the mixed fluid to photoradiation sufficient to activate the photosensitizer whereby at least some of the pathogens are reduced.

29 . The method of claim 28 wherein the collected blood component comprises platelets.

30 . The method of claim 28 further comprising adding physiological saline to the mixed fluid.

31 . The method of claim 29 wherein the mixed fluid further comprises plasma in an amount between 20-80 mL per 10 11 collected platelets.

32 . The method of claim 29 wherein the mixed fluid further comprises plasma in an amount between 30-60 mL per 10 11 collected platelets.